Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years in high-risk patient population

NATICK, Mass., and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced four-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system -- which is not approved for commercial distribution -- were maintained at four years with no new stent thrombosis reported after two years. Analysis of the data was presented by Professor Eberhard Grube, M.D., Heart Center Siegburg, Germany, the Co- Principal Investigator of the trial. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

"Even though the moderate-release TAXUS formulation, with an 8-10 fold higher in vitro dose, was never commercialized, the excellent ongoing results in TAXUS VI further demonstrate the margin of safety of the commercial slow- release TAXUS stent now implanted in more than four million patients worldwide," said Paul LaViolette, Boston Scientific Chief Operating Officer. "With no stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population."

"The four-year results from TAXUS VI demonstrate that the safety and efficacy benefits associated with the moderate-release TAXUS paclitaxel- eluting stent system were maintained in patients with complex coronary artery disease at four years," said Professor Grube. "The performance of the TAXUS stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents."

The randomized, double-blind, co
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:7/28/2014)... FRANCISCO , July 28, 2014  Dignity ... it has received the Get With The Guidelines®-Stroke ... improvement measures outlined by the American Heart Association/American ... Stroke is the number four cause of death ... the United States , according ...
(Date:7/28/2014)... Calif. , July 28, 2014 STAAR ... developer, manufacturer and marketer of implantable lenses and delivery ... its second quarter results and conference call with investors ... July 30, 2014.  The Company rescheduled the release date ... the funeral services for Hideo Watanabe , President ...
(Date:7/28/2014)... July 28, 2014  MiMedx Group, Inc. (NASDAQ: MDXG ... regenerative biomaterials and bioimplants processed from human amniotic membrane, announced ... Highlights include: , Revenue exceeds ... 2013 to $25.6 million , Quarter-over-quarter ... Care revenue increases 181% over Q2 2013 and 40% sequentially ...
Breaking Medicine Technology:Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm traditionally specializing ... industry veteran Daryl Demonbreun and former St. Thomas executive ... ambitious plans to grow into a full-service health care ... at a steady pace for nearly 20 years, but ... Bob Maier, founder and chief executive officer of Regents ...
(Date:7/29/2014)... 29, 2014 Intermedix Corporation is proud ... Data eXchange. , The Clinical Data eXchange, or CDX, ... pre-hospital patient care data. , With this solution, state ... accept imports of NEMSIS 3.0 compliant data from multiple ... to be accessed, analyzed, and reported to the national ...
(Date:7/29/2014)... There is controversy over how best to treat patients ... one wait until the cancer comes back or provide ... Now, a new study from Thomas Jefferson ... doctors and patients make a more informed decision. , ... says first author Robert Den, M.D., Assistant Professor of ...
(Date:7/29/2014)... procedure may enable more widespread use of preoperative testing ... with severe sleep apnea, suggests a study in ... and Dr. Jeff E. Mandel of the University of ... control" anesthetic technique for putting patients to sleep briefly-just ... apnea. The simplified technique requires no special expertise and ...
Breaking Medicine News(10 mins):Health News:OZ Naturals to Launch Its Products in the UK 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Intermedix Releases NEMSIS Compliant EMS Information System 2Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 2Health News:New anesthesia technique helps show cause of obstruction in sleep apnea 3
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Dec. ... the drug Avastin may lengthen progression-free survival by about four ... yet is whether adding Avastin (bevacizumab) will make a difference ... other study didn,t find a difference in overall survival between ...
... 28, 2011. The 2011 revision of the International Standards ... was published in the November 2011 issue of the ... reference article by Steven Kirshblum et al clarifies the ... free download via http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ...
... Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the ... an international clinical trial co-led by Drs. Amit Oza of ... Perren, St James,s Institute of Oncology, Leeds, UK. ... of Medicine, report that the drug halted the cancer,s ...
... Goodwin HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay ... acids and vitamins B, C, D and E in their ... also tended to have larger brain volume, a new study ... their blood fared worse on certain thinking tests than those ...
... News) -- A new examination of the origin of syphilis ... to Europe aboard Christopher Columbus, ships as they sailed ... not spread through sexual contact at the time, but adapted ... say. "Syphilis has been around for 500 years," ...
... , WEDNESDAY, Dec. 28 (HealthDay News) -- Knowing ... may lead to an early diagnosis, experts say. According ... Plan ahead for the future. , Potentially take part ... help maintain independence for a longer time and possibly improve ...
Cached Medicine News:Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 2Health News:Vitamins, Omega-3s May Keep Brain From Shrinking: Study 3Health News:Columbus Voyage Tied to Syphilis Spread? 2Health News:Know the Signs of Alzheimer's 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: